Previous close | 1.5400 |
Open | 1.5100 |
Bid | 1.5600 x 100 |
Ask | 1.6300 x 100 |
Day's range | 1.4500 - 1.6200 |
52-week range | 0.6220 - 2.5000 |
Volume | |
Avg. volume | 205,204 |
Market cap | 26.119M |
Beta (5Y monthly) | 2.36 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.9600 |
Earnings date | 10 May 2024 - 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.50 |
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has resubmitte
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript March 28, 2024 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.02. ITRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, everyone, and welcome to the […]
Q4 2023 Iterum Therapeutics PLC Earnings Call